Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Philip J. Johnson(Prince of Wales Hospital), Hidenori Toyoda(Ogaki Municipal Hospital), Paul B.S. Lai(Chinese University of Hong Kong), Mabel Teng(University of Cambridge), Daniel H. Palmer(University of Liverpool), James O’Beirne(The Honourable Society of Lincoln's Inn), Rebecca A. Miksad(Brigham and Women's Hospital), Shinji Satomura(University of Cambridge), Chiaki Kagebayashi(University of Cambridge), Takashi Kumada(Gifu Kyoritsu University), Mercedes Iñarrairaegui(University of Cambridge), Stephen L. Chan(Chinese University of Hong Kong), Anna Skowrońska(University of Cambridge), Toshifumi Tada(Himeji Red Cross Hospital), Helen L. Reeves(Newcastle upon Tyne Hospital), Bruno Sangro(Clinica Universidad de Navarra), Sarah Berhane(University Hospitals Birmingham NHS Foundation Trust), Frankie Mo(Chinese University of Hong Kong), Richard Fox(Cancer Research UK Clinical Trials Unit), Winnie Yeo(Chinese University of Hong Kong)
Cited by 2,809
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k